EMV · ASX

EMvision Medical Devices Ltd. (ASX:EMV)

AU$1.94

 0.035 (1.842%)
ASX:Live
09/05/2025 01:38:59 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

EMV Overview

EMV Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About EMV

Website

EMvision Medical Devices Ltd.

Telephone

61.2.8667.5337

Address

Suite 4.01 65 Epping Road Macquarie Park, New South Wales (NSW) 2113

Description

EMvision Medical Devices Ltd. engages in the development & commercialization of medical imaging technology. The company was founded on July 11, 2017, and is headquartered in Brisbane, Australia.

EMV Price Chart

Key Stats

Market Cap

AU$166.97M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 1.71 - 2.35

Trade Value (12mth)

AU$16,976.00

1 week

1.06%

1 month

5.56%

YTD

1.06%

1 year

-5.94%

All time high

4.20

Key Fundamentals

EPS 3 yr Growth

-71.70%

EBITDA Margin

N/A

Operating Cashflow

-$6m

Free Cash Flow Return

-46.50%

ROIC

-21.20%

Interest Coverage

-112.90

Quick Ratio

6.40

Other Data

Shares on Issue (Fully Dilluted)

85m

HALO Sector

Healthcare

Next Company Report Date

02-Sep-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

EMV Announcements

Latest Announcements

Date Announcements

30 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

28 April 25

Activation of Second US Pivotal Trial Site, Mayo Clinic

×

Activation of Second US Pivotal Trial Site, Mayo Clinic

16 April 25

Non-Executive Director Retirement

×

Non-Executive Director Retirement

16 April 25

Final Director's Interest Notice

×

Final Director's Interest Notice

27 March 25

Emu Pivotal Validation Trial Commences

×

Emu Pivotal Validation Trial Commences

21 March 25

Change of Share Registry Details

×

Change of Share Registry Details

19 March 25

First Responder Scanner in Successful Aeromedical Testing

×

First Responder Scanner in Successful Aeromedical Testing

07 March 25

S&P DJI Announces March 2025 Quarterly Rebalance

×

S&P DJI Announces March 2025 Quarterly Rebalance

27 February 25

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

27 February 25

EMVision Releases its FY25 Half Yearly Report

×

EMVision Releases its FY25 Half Yearly Report

12 February 25

US Ethics Approval Received for Pivotal Validation Trial

×

US Ethics Approval Received for Pivotal Validation Trial

28 January 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

20 January 25

EMVision Receives $2.12m R&D Tax Rebate

×

EMVision Receives $2.12m R&D Tax Rebate

02 December 24

Notification of cessation of securities - EMV

×

Notification of cessation of securities - EMV

28 November 24

Presentation - Ord Minnett Biotech & Medtech Conference

×

Presentation - Ord Minnett Biotech & Medtech Conference

20 November 24

Notification regarding unquoted securities - EMV

×

Notification regarding unquoted securities - EMV

20 November 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

15 November 24

Results of Annual General Meeting

×

Results of Annual General Meeting

14 November 24

AGM Chair's Address & MD Presentation

×

AGM Chair's Address & MD Presentation

12 November 24

Algorithms Deliver Excellent Results In EMView Study

×

Algorithms Deliver Excellent Results In EMView Study

30 October 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 October 24

EMV Prepares for Trial Following Positive FDA Engagement

×

EMV Prepares for Trial Following Positive FDA Engagement

25 October 24

Notification of cessation of securities - EMV

×

Notification of cessation of securities - EMV

11 October 24

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

18 September 24

Date of AGM & Closing Date for Director Nominations

×

Date of AGM & Closing Date for Director Nominations

EMV Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.08 -0.05 -0.03 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.08 -0.05 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock 32.2 38.7 31.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A 49.1 N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A 0.0 N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.05 -0.02 -0.02 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.05 0.01 -0.08 Lock Lock Lock
     Growth % Lock Lock Lock Lock 15.1 60.1 23.3 Lock Lock Lock
     Yield % Lock Lock Lock Lock -3.5 0.7 -3.5 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A 0.0 N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.09 0.07 0.22 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.09 0.06 0.21 Lock Lock Lock
     Growth % Lock Lock Lock Lock -36.0 -30.0 251.5 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 75 78 80 Lock Lock Lock
Basic m Lock Lock Lock Lock 75 78 80 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 10 11 13 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -113.5 -40.5 -20.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -10 -11 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -1.5 -3.5 -23.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -10 -11 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -2.8 -4.4 -23.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -8 -6 -9 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -3 -6 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -6 -4 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock 27.3 36.6 29.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -4 1 -6 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 1 3 15 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -4 1 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock 14.0 116.3 -1,044.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 7 10 19 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 9 12 24 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 0 2 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -6 -7 -16 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 6 5 Lock Lock Lock
Equity $m Lock Lock Lock Lock 7 5 19 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 8 5 20 Lock Lock Lock
     Growth % Lock Lock Lock Lock -24.5 -28.8 274.9 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -71.8 -33.6 -11.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -86.3 -75.7 -14.7 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -115.7 -136.8 -91.1 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -69.0 -59.3 -21.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -42.7 12.8 -46.5 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -564.2 -300.1 -112.9 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.6 0.7 1.2 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -85.6 -135.4 -84.8 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 8.3 1.7 6.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 8.3 1.7 6.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 96.2 97.4 85.1 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -442.9 13.8 -175.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -71.8 -33.6 -11.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 2.3 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -86.3 -75.7 -14.7 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -86.3 -75.7 -14.7 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 278.9 271.6 277.4 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -278.9 -271.6 -277.4 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

EMV Shortsell

Frequently Asked Questions

The current share price of EMvision Medical Devices Ltd. (EMV:ASX) is AU$1.94.
The 52-week high share price for EMvision Medical Devices Ltd. (EMV:ASX) is AU$2.35.
The 52-week low share price for EMvision Medical Devices Ltd. (EMV:ASX)? is AU$1.71.
EMvision Medical Devices Ltd. (EMV:ASX) does not pay a dividend.
EMvision Medical Devices Ltd. (EMV:ASX) does not pay a dividend.
EMvision Medical Devices Ltd. (EMV:ASX) does not offer franking credits.
EMvision Medical Devices Ltd. (EMV:ASX) is classified in the Healthcare.
The current P/E ratio for EMvision Medical Devices Ltd. (EMV:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.